{
    "protocolSection": {
        "identificationModule": {
            "nctId": "NCT06305806",
            "orgStudyIdInfo": {
                "id": "Pro00112597_B"
            },
            "secondaryIdInfos": [
                {
                    "id": "OTA-21-015G",
                    "type": "OTHER",
                    "domain": "NIH Grant to RTI; RTI subcontracting with DCRI"
                }
            ],
            "organization": {
                "fullName": "Duke University",
                "class": "OTHER"
            },
            "briefTitle": "RECOVER-AUTONOMIC: Platform Protocol, Appendix B (Ivabradine)",
            "officialTitle": "RECOVER-AUTONOMIC (Ivabradine): Randomized Trial of the Effect of Ivabradine Versus Placebo on Long COVID Symptoms",
            "therapeuticArea": [
                "Infectious Diseases"
            ],
            "study": "recover-autonomic-platform-protocol-appendix-b-ivabradine"
        },
        "statusModule": {
            "statusVerifiedDate": "2024-06",
            "overallStatus": "RECRUITING",
            "expandedAccessInfo": {
                "hasExpandedAccess": false
            },
            "startDateStruct": {
                "date": "2024-03-11",
                "type": "ACTUAL"
            },
            "primaryCompletionDateStruct": {
                "date": "2025-12",
                "type": "ESTIMATED"
            },
            "completionDateStruct": {
                "date": "2026-03",
                "type": "ESTIMATED"
            },
            "studyFirstSubmitDate": "2024-03-04",
            "studyFirstSubmitQcDate": "2024-03-08",
            "studyFirstPostDateStruct": {
                "date": "2024-03-12",
                "type": "ACTUAL"
            },
            "lastUpdateSubmitDate": "2024-06-26",
            "lastUpdatePostDateStruct": {
                "date": "2024-06-27",
                "type": "ACTUAL"
            }
        },
        "sponsorCollaboratorsModule": {
            "responsibleParty": {
                "type": "SPONSOR_INVESTIGATOR",
                "investigatorFullName": "Kanecia Obie Zimmerman",
                "investigatorTitle": "Associate Professor of Pediatrics",
                "investigatorAffiliation": "Duke University"
            },
            "leadSponsor": {
                "name": "Kanecia Obie Zimmerman",
                "class": "OTHER"
            }
        },
        "oversightModule": {
            "oversightHasDmc": true,
            "isFdaRegulatedDrug": true,
            "isFdaRegulatedDevice": false
        },
        "descriptionModule": {
            "briefSummary": "This study is a platform protocol designed to be flexible so that it is suitable for a wide range of settings within health care systems and in community settings where it can be integrated into COVID-19 programs and subsequent treatment plans.\n\nThis protocol is a prospective, multi-center, multi-arm, randomized, controlled platform trial evaluating various interventions for use in the treatment of autonomic dysfunction symptoms, including cardiovascular complications and postural orthostatic tachycardia syndrome (POTS), in PASC participants. The interventions tested will include non-pharmacologic care and pharmacologic therapies with study drugs.",
            "detailedDescription": "The hypothesis is that some of the autonomic dysfunction symptoms are immune-mediated, so immunotherapy and other applicable therapies will result in improvement in autonomic symptoms.\n\nInterventions will be added to the platform protocol as appendices. Each appendix will leverage all elements of the platform protocol, with additional elements described in the individual appendix."
        },
        "conditionsModule": {
            "conditions": [
                "Long COVID",
                "Long Covid19",
                "Long Covid-19"
            ],
            "keywords": [
                "PASC",
                "POTS"
            ]
        },
        "designModule": {
            "studyType": "INTERVENTIONAL",
            "phases": [
                "PHASE2"
            ],
            "designInfo": {
                "allocation": "RANDOMIZED",
                "interventionModel": "PARALLEL",
                "interventionModelDescription": "In each Appendix trial, each participant will be assigned with equal probability to one of the factorial combinations based on two factors: (1) a study intervention/control and (2) non-pharmacologic intervention/control if the participant is eligible for the study intervention.",
                "primaryPurpose": "TREATMENT",
                "maskingInfo": {
                    "masking": "TRIPLE",
                    "maskingDescription": "Double blind",
                    "whoMasked": [
                        "PARTICIPANT",
                        "CARE_PROVIDER",
                        "INVESTIGATOR"
                    ]
                }
            },
            "enrollmentInfo": {
                "count": 180,
                "type": "ESTIMATED"
            }
        },
        "armsInterventionsModule": {
            "armGroups": [
                {
                    "label": "Ivabradine + Coordinated Care",
                    "type": "EXPERIMENTAL",
                    "description": "The starting dose will be 5 mg twice a day, and the dose will be modified if needed at the 1 month clinic visit. At this visit, HR will be measured and the dose will be modified as applicable. The maximum dose will be 7.5 mg twice daily if HR is \u02c3 90 bpm.\n\nThe table below provides the dosing of ivabradine based on HR.\n\nSupine Resting HR 60-80 2.5 mg BID Supine Resting HR \\>80 5 mg BID Supine Resting HR \\>90 7.5 mg BID\n\n\\*Resting HR should be measured 5 minutes after lying down",
                    "interventionNames": [
                        "Drug: Ivabradine",
                        "Behavioral: Coordinated Care"
                    ]
                },
                {
                    "label": "Ivabradine Placebo + Coordinated Care",
                    "type": "EXPERIMENTAL",
                    "interventionNames": [
                        "Drug: Ivabradine Placebo",
                        "Behavioral: Coordinated Care"
                    ]
                },
                {
                    "label": "Ivabradine + Usual Care",
                    "type": "EXPERIMENTAL",
                    "description": "The starting dose will be 5 mg twice a day, and the dose will be modified if needed at the 1 month clinic visit. At this visit, HR will be measured and the dose will be modified as applicable. The maximum dose will be 7.5 mg twice daily if HR is \u02c3 90 bpm.\n\nThe table below provides the dosing of ivabradine based on HR.\n\nSupine Resting HR 60-80 2.5 mg BID Supine Resting HR \\>80 5 mg BID Supine Resting HR \\>90 7.5 mg BID\n\n\\*Resting HR should be measured 5 minutes after lying down",
                    "interventionNames": [
                        "Drug: Ivabradine",
                        "Behavioral: Usual Care"
                    ]
                },
                {
                    "label": "Ivabradine Placebo + Usual Care",
                    "type": "EXPERIMENTAL",
                    "interventionNames": [
                        "Drug: Ivabradine Placebo",
                        "Behavioral: Usual Care"
                    ]
                }
            ],
            "interventions": [
                {
                    "type": "DRUG",
                    "name": "Ivabradine",
                    "description": "Participants will receive ivabradine for 3 months (12 weeks) with a follow-up period for an additional 3 months (total study duration of 6 months).",
                    "armGroupLabels": [
                        "Ivabradine + Coordinated Care",
                        "Ivabradine + Usual Care"
                    ]
                },
                {
                    "type": "DRUG",
                    "name": "Ivabradine Placebo",
                    "description": "The control (placebo) oral tablets will be similar to the study drug, ivabradine.\n\nThe control packaging matches the packaging.\n\nParticipants will receive placebo for 3 months (12 weeks) with a follow-up period for an additional 3 months (total study duration of 6 months).",
                    "armGroupLabels": [
                        "Ivabradine Placebo + Coordinated Care",
                        "Ivabradine Placebo + Usual Care"
                    ]
                },
                {
                    "type": "BEHAVIORAL",
                    "name": "Coordinated Care",
                    "description": "Participants will receive coordinated non-pharmacologic care for a duration of 3 months, concurrent with ivabradine administration. Coordinated non-pharmacologic care involves volume expansion through high salt diet, water intake, abdominal binder, exercise/rehabilitation, motivation, education, and assisted care through care coordinator.",
                    "armGroupLabels": [
                        "Ivabradine + Coordinated Care",
                        "Ivabradine Placebo + Coordinated Care"
                    ]
                },
                {
                    "type": "BEHAVIORAL",
                    "name": "Usual Care",
                    "description": "Participants will receive usual non-pharmacologic care (control) for a duration of 3 months, concurrent with ivabradine administration.",
                    "armGroupLabels": [
                        "Ivabradine + Usual Care",
                        "Ivabradine Placebo + Usual Care"
                    ]
                }
            ]
        },
        "outcomesModule": {
            "primaryOutcomes": [
                {
                    "measure": "Change in Orthostatic Hypotension Questionnaire (OHQ)/Orthostatic Intolerance Questionnaire (OIQ) Composite Score",
                    "description": "The OHQ / OIQ is a measure of orthostatic intolerance and includes a 6-item symptom assessment (OHSA) and the 4-item Daily Activity Scale (OHDAS). Each item is scored from 0 (none/no interference) to 10 (worst possible/complete interference), describing the preceding week. The OHSA composite score is the average of the first 6 non-zero items and the OHDAS composite score is the average of the last 4 non-zero items. The OHQ/OIQ composite score is the average of the OHSA and OHDAS composite scores. The OHQ/OIQ scales at post-baseline are calculated using only those items that were included in the baseline scores.",
                    "timeFrame": "Baseline to End of Intervention (3 months)"
                }
            ],
            "secondaryOutcomes": [
                {
                    "measure": "Change in Composite Autonomic Symptoms Score 31 (COMPASS-31)",
                    "description": "The COMPASS-31 is a patient reported outcome that measures autonomic symptoms across multiple domains commonly seen in patients with PASC. Scores range from 0-100 with higher values representing severe symptoms.",
                    "timeFrame": "Baseline to End of Intervention (3 months)"
                },
                {
                    "measure": "Change in Malmo POTS Symptom Score",
                    "description": "The Malmo POTS symptom score assesses symptom burden in postural orthostatic tachycardia syndrome (POTS). It is a self-rating, 12-item score (0-10 per item, total range 0-120) based on patients' own perception of symptoms through visual analogue scale assessment. Higher scores represent more pronounced symptoms.",
                    "timeFrame": "Baseline to End of Intervention (3 months)"
                },
                {
                    "measure": "Change in Active Stand Test",
                    "description": "Participants will remain supine for 10 minutes, and data will be acquired at 5 and 10 minutes. Standing test should be performed with HR and BP monitoring at 1, 3, 5 and 10 minutes",
                    "timeFrame": "Baseline to End of Intervention (3 months)"
                },
                {
                    "measure": "Change in blood pressure (BP)",
                    "description": "measured during Active Stand Test",
                    "timeFrame": "Baseline to End of Intervention (3 months)"
                },
                {
                    "measure": "Change in heart rate (HR)",
                    "description": "measured during Active Stand Test",
                    "timeFrame": "Baseline to End of Intervention (3 months)"
                },
                {
                    "measure": "Change in 6-min Walk Test",
                    "description": "Normal walking speed will be measured using a standard 6 minute walk",
                    "timeFrame": "Baseline to End of Intervention (3 months)"
                },
                {
                    "measure": "Change in PROMIS-29 + 2 Questionnaire",
                    "description": "The PROMIS-29 consists of 29 items that assess general domains of health and functioning, including overall physical health, mental health, social health, pain, fatigue, and overall perceived quality of life.\n\nThe PROMIS-29+2 is used to calculate a preference score (PROPr) by the addition of two Cognitive Function Ability items. Scores will be reported as T scores ranging from 0 to 100, with a score of 60 being 1 standard deviation above the mean. Higher scores indicate worse overall health.",
                    "timeFrame": "Baseline to End of Intervention (3 months)"
                },
                {
                    "measure": "Change in step count as measured by a wearable device",
                    "description": "measured by a wearable device",
                    "timeFrame": "Baseline to End of Intervention (3 months)"
                },
                {
                    "measure": "Change in heart rate as measured by a wearable device",
                    "description": "measured by a wearable device",
                    "timeFrame": "Baseline to End of Intervention (3 months)"
                },
                {
                    "measure": "Proportion of participants who experience individual SAEs",
                    "description": "These will be analyzed in the safety population.",
                    "timeFrame": "Baseline to Follow-up (6 months)"
                },
                {
                    "measure": "Proportion who experience any one or more SAEs",
                    "description": "These will be analyzed in the safety population.",
                    "timeFrame": "Baseline to Follow-up (6 months)"
                },
                {
                    "measure": "Incidence of SAEs leading to discontinuation",
                    "description": "These will be analyzed in the safety population.",
                    "timeFrame": "Baseline to Follow-up (6 months)"
                },
                {
                    "measure": "Incidence of Events of Special Interest (ESIs)",
                    "description": "Each study drug may have a unique list of ESIs",
                    "timeFrame": "Baseline to Follow-up (6 months)"
                }
            ],
            "otherOutcomes": [
                {
                    "measure": "Changes in Autonomic Function Testing",
                    "description": "* Head-up tilt (HUT) test\n* Valsalva maneuver with a pressure of 40 mmHg for 15 seconds\n* Deep breathing test\n* Skin biopsy (if applicable as per Appendix)\n* Transcranial doppler (TCD), if available",
                    "timeFrame": "Baseline to End of Intervention (3 months)"
                },
                {
                    "measure": "Change in Vanderbilt Orthostatic Symptoms Score (VOSS)",
                    "description": "The VOSS consists of 9 orthostatic symptoms rated on a scale of 0 (no symptom) to 10 (worst the participant has experienced) at the end of each Head-up Tilt test. Scores range from 0-90 with higher scores representing worse symptoms.",
                    "timeFrame": "Baseline to End of Intervention (3 months)"
                },
                {
                    "measure": "Change in PASC Symptom Questionnaire",
                    "description": "Participants will be asked to complete a questionnaire that asks about the presence of PASC symptoms. This questionnaire includes additional PASC symptoms that are not directly related to autonomic dysfunction.",
                    "timeFrame": "Baseline to End of Intervention (3 months)"
                }
            ]
        },
        "eligibilityModule": {
            "eligibilityCriteria": "Inclusion Criteria:\n\n* See NCT06305780 for RECOVER-AUTO: Platform Protocol level inclusion criteria which applies to this appendix (or sub-study)\n\nAdditional Appendix B (Ivabradine Sub-study) Level Inclusion Criteria:\n\n1. Abnormal active standing test defined as presence of orthostatic tachycardia (an increase of 30 beats per minute (bpm) or more in HR within 10 minutes upon standing without orthostatic hypotension) and experiencing orthostatic symptoms\n2. COMPASS-31 Score \\> 25 and not enrolled in the IVIG appendix\n\nExclusions Criteria:\n\n* See NCT06305780 for RECOVER-AUTO: Platform Protocol level inclusion criteria which applies to this appendix (or sub-study)\n\nAdditional Appendix B (Ivabradine Sub-study) Level Exclusion Criteria:\n\n1. A person of child-bearing potential who is not taking effective contraception\n2. Use of the following medications: clonidine, tizanidine, amphetamines, and serotonin and norepinephrine reuptake inhibitors (SNRIs) with the exception of modafinil\n3. Use of beta-blockers (any formulation), calcium channel blockers, midodrine, pyridostigmine, fludrocortisone, and guanfacine will be excluded unless participant is on a stable dose (\\>4 weeks). Participants on stable doses will be allowed to continue the medication throughout the study.\n4. Combination with verapamil or diltiazem which are moderate CYP3A4 inhibitors with heart rate reducing properties\n5. Lactating and breast-feeding women\n6. Severe hepatic impairment\n7. Use of drugs known to prolong the QT-interval (e.g., quinidine, disopyramide, bepridil, sotalol, amiodarone, pimozide, ziprasidone, sertindole, mefloquine, halofantrine, pentamidine\n8. Concomitant use of digoxin\n9. Participants who are pacemaker dependent\n10. Patients with hypokalemia (serum K+\\<3.5 mEq/L)\n11. Patients taking potassium-depleting diuretics\n12. A history of congenital or acquired long QT syndrome, with or without torsade de pointes\n13. Patients with high degree AV block such as Mobitz II",
            "healthyVolunteers": false,
            "sex": "ALL",
            "minimumAge": "18 Years",
            "stdAges": [
                "ADULT",
                "OLDER_ADULT"
            ]
        },
        "contactsLocationsModule": {
            "centralContacts": [
                {
                    "name": "Orshi Moy",
                    "role": "CONTACT",
                    "phone": "919-668-8060",
                    "email": "recoverresearch@duke.edu"
                },
                {
                    "name": "Barrie L Harper, BSMT(ASCP)PMP",
                    "role": "CONTACT",
                    "email": "recoverresearch@duke.edu"
                }
            ],
            "overallOfficials": [
                {
                    "name": "Christopher Grainger, MD",
                    "affiliation": "Duke Clinical Research Institute",
                    "role": "STUDY_CHAIR"
                },
                {
                    "name": "Cyndya Shibao, MD",
                    "affiliation": "Vanderbilt University Medical Center",
                    "role": "STUDY_CHAIR"
                },
                {
                    "name": "Peter Novak, MD",
                    "affiliation": "Harvard",
                    "role": "STUDY_CHAIR"
                },
                {
                    "name": "Pam Taub, MD",
                    "affiliation": "University of California, San Diego",
                    "role": "STUDY_CHAIR"
                },
                {
                    "name": "Tae Chung, MD",
                    "affiliation": "Johns Hopkins University",
                    "role": "STUDY_CHAIR"
                }
            ],
            "locations": [
                {
                    "facility": "All sites listed under NCT06305780",
                    "status": "RECRUITING",
                    "city": "Durham",
                    "state": "North Carolina",
                    "zip": "27710",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 35.99403,
                        "lon": -78.89862
                    }
                }
            ]
        },
        "referencesModule": {
            "seeAlsoLinks": [
                {
                    "label": "Related Info",
                    "url": "http://recovercovid.org/"
                }
            ]
        },
        "ipdSharingStatementModule": {
            "ipdSharing": "NO",
            "description": "The summary of results will be shared on the study website: https://recovercovid.org/"
        }
    },
    "derivedSection": {
        "miscInfoModule": {
            "versionHolder": "2024-07-30"
        },
        "conditionBrowseModule": {
            "meshes": [
                {
                    "id": "D000086382",
                    "term": "COVID-19"
                },
                {
                    "id": "D000094024",
                    "term": "Post-Acute COVID-19 Syndrome"
                }
            ],
            "ancestors": [
                {
                    "id": "D000011024",
                    "term": "Pneumonia, Viral"
                },
                {
                    "id": "D000011014",
                    "term": "Pneumonia"
                },
                {
                    "id": "D000012141",
                    "term": "Respiratory Tract Infections"
                },
                {
                    "id": "D000007239",
                    "term": "Infections"
                },
                {
                    "id": "D000014777",
                    "term": "Virus Diseases"
                },
                {
                    "id": "D000018352",
                    "term": "Coronavirus Infections"
                },
                {
                    "id": "D000003333",
                    "term": "Coronaviridae Infections"
                },
                {
                    "id": "D000030341",
                    "term": "Nidovirales Infections"
                },
                {
                    "id": "D000012327",
                    "term": "RNA Virus Infections"
                },
                {
                    "id": "D000008171",
                    "term": "Lung Diseases"
                },
                {
                    "id": "D000012140",
                    "term": "Respiratory Tract Diseases"
                },
                {
                    "id": "D000094025",
                    "term": "Post-Infectious Disorders"
                },
                {
                    "id": "D000002908",
                    "term": "Chronic Disease"
                },
                {
                    "id": "D000020969",
                    "term": "Disease Attributes"
                },
                {
                    "id": "D000010335",
                    "term": "Pathologic Processes"
                }
            ],
            "browseLeaves": [
                {
                    "id": "M3013",
                    "name": "Post-Acute COVID-19 Syndrome",
                    "asFound": "Long COVID",
                    "relevance": "HIGH"
                },
                {
                    "id": "M2561",
                    "name": "COVID-19",
                    "asFound": "COVID-19",
                    "relevance": "HIGH"
                },
                {
                    "id": "M16355",
                    "name": "Syndrome",
                    "relevance": "LOW"
                },
                {
                    "id": "M13904",
                    "name": "Pneumonia",
                    "relevance": "LOW"
                },
                {
                    "id": "M13914",
                    "name": "Pneumonia, Viral",
                    "relevance": "LOW"
                },
                {
                    "id": "M10283",
                    "name": "Infections",
                    "relevance": "LOW"
                },
                {
                    "id": "M6368",
                    "name": "Communicable Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M14978",
                    "name": "Respiratory Tract Infections",
                    "relevance": "LOW"
                },
                {
                    "id": "M17522",
                    "name": "Virus Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M20490",
                    "name": "Coronavirus Infections",
                    "relevance": "LOW"
                },
                {
                    "id": "M6555",
                    "name": "Coronaviridae Infections",
                    "relevance": "LOW"
                },
                {
                    "id": "M23685",
                    "name": "Nidovirales Infections",
                    "relevance": "LOW"
                },
                {
                    "id": "M15149",
                    "name": "RNA Virus Infections",
                    "relevance": "LOW"
                },
                {
                    "id": "M11168",
                    "name": "Lung Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M14977",
                    "name": "Respiratory Tract Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M3014",
                    "name": "Post-Infectious Disorders",
                    "relevance": "LOW"
                },
                {
                    "id": "M6147",
                    "name": "Chronic Disease",
                    "relevance": "LOW"
                },
                {
                    "id": "M22700",
                    "name": "Disease Attributes",
                    "relevance": "LOW"
                },
                {
                    "id": "T170",
                    "name": "Acute Graft Versus Host Disease",
                    "relevance": "LOW"
                },
                {
                    "id": "T1303",
                    "name": "Chronic Graft Versus Host Disease",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "BC01",
                    "name": "Infections"
                },
                {
                    "abbrev": "BC08",
                    "name": "Respiratory Tract (Lung and Bronchial) Diseases"
                },
                {
                    "abbrev": "BC23",
                    "name": "Symptoms and General Pathology"
                },
                {
                    "abbrev": "All",
                    "name": "All Conditions"
                },
                {
                    "abbrev": "Rare",
                    "name": "Rare Diseases"
                }
            ]
        }
    },
    "hasResults": false
}